Liver, Phase III
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan, PA
- Armand Russo, MD
- Caitlin Gallagher, APRN
- Clarice Grens, APRN
- D. Barry Boyd, MD, MS
- Elizabeth Gaa, APRN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Jill Lacy, MD
- Julia Marie DiBartolomeo, APRN
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Kert Sabbath, MD, FACP
- Matthew Austin, MD
- Megan Shulman, APRN
- Michael Cecchini, MD
- Michael Grant, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Raghav Sundar, MD, PhD
- Sara Anastasio, APRN, RN
- Sharynn Hall, MD, PhD
- Stacey LaRosa, APRN
- Teresa White, APRN
- Thejal Srikumar, MD, MPH
- Victor Chang, MD
- Virginia Syombathy, APRN
- Xiao Wang, MD
- Yifei Zhang, MD
- Last Updated03/20/2026
- Study IRB#2000040515